DK1000048T3 - Substituerede 1,2,3,4-tetrahydronapthalenderivater - Google Patents

Substituerede 1,2,3,4-tetrahydronapthalenderivater

Info

Publication number
DK1000048T3
DK1000048T3 DK98934104T DK98934104T DK1000048T3 DK 1000048 T3 DK1000048 T3 DK 1000048T3 DK 98934104 T DK98934104 T DK 98934104T DK 98934104 T DK98934104 T DK 98934104T DK 1000048 T3 DK1000048 T3 DK 1000048T3
Authority
DK
Denmark
Prior art keywords
tetrahydronaphthalane
derivatives
substituted
tetrahydronaphthalane derivatives
Prior art date
Application number
DK98934104T
Other languages
Danish (da)
English (en)
Inventor
Stefan Berg
Mats Linderberg
Svante Ross
Seth-Olov Thorberg
Bengt Ulff
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1000048T3 publication Critical patent/DK1000048T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98934104T 1997-07-25 1998-07-15 Substituerede 1,2,3,4-tetrahydronapthalenderivater DK1000048T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702799A SE9702799D0 (sv) 1997-07-25 1997-07-25 New compounds
PCT/SE1998/001390 WO1999005134A1 (fr) 1997-07-25 1998-07-15 Derives de 1,2,3,4-tetrahydronaphthalene substitue

Publications (1)

Publication Number Publication Date
DK1000048T3 true DK1000048T3 (da) 2003-03-03

Family

ID=20407828

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98934104T DK1000048T3 (da) 1997-07-25 1998-07-15 Substituerede 1,2,3,4-tetrahydronapthalenderivater

Country Status (36)

Country Link
US (3) US6313118B1 (fr)
EP (1) EP1000048B1 (fr)
JP (1) JP3895923B2 (fr)
KR (1) KR20010022171A (fr)
CN (1) CN1270585A (fr)
AR (2) AR013370A1 (fr)
AT (1) ATE228510T1 (fr)
AU (1) AU739569B2 (fr)
BR (1) BR9811042A (fr)
CA (1) CA2296518A1 (fr)
DE (1) DE69809755T2 (fr)
DK (1) DK1000048T3 (fr)
DZ (1) DZ2569A1 (fr)
EE (1) EE04238B1 (fr)
ES (1) ES2187983T3 (fr)
HR (1) HRP980404B1 (fr)
HU (1) HUP0004334A3 (fr)
ID (1) ID24583A (fr)
IL (1) IL134108A0 (fr)
IS (1) IS5358A (fr)
MA (1) MA26521A1 (fr)
NO (1) NO315609B1 (fr)
NZ (1) NZ502384A (fr)
PL (1) PL338563A1 (fr)
PT (1) PT1000048E (fr)
RU (1) RU2194696C2 (fr)
SE (1) SE9702799D0 (fr)
SI (1) SI1000048T1 (fr)
SK (1) SK283918B6 (fr)
TN (1) TNSN98141A1 (fr)
TR (1) TR200000229T2 (fr)
TW (1) TW438781B (fr)
UA (1) UA69389C2 (fr)
WO (1) WO1999005134A1 (fr)
YU (1) YU2300A (fr)
ZA (1) ZA986588B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0002729D0 (sv) * 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
AR034206A1 (es) * 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
SE0102856D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab A new method
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
US7101881B2 (en) * 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
MXPA06013520A (es) * 2004-05-21 2007-01-26 Pfizer Prod Inc Tetrahironaftilpiperazinas como antagonistas, agonistas inversos y agonistas parciales de 5-ht1b.
CN102114244A (zh) * 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
US20080033050A1 (en) * 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
WO2008130323A1 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux dérivés 8-pipérazine-tétrahydronaphtalène utilisés pour le traitement de la douleur
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
WO2008130319A2 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux composés 805
WO2008130322A1 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux dérivés 5-hétérocyclyl-chromane utilisés pour le traitement de la douleur
WO2008130321A2 (fr) * 2007-04-23 2008-10-30 Astrazeneca Ab Nouveaux composés 807
EP2098511A1 (fr) 2008-03-07 2009-09-09 Solvias AG Procédé pour la préparation de composés contenant une structure d'hydronaphtalène avec un cycle benzène à substitution asymétrique
MX2010014203A (es) 2008-06-20 2011-02-22 Astrazeneca Ab Derivados de dibenzotiazepina y sus usos - 424.
GB201002563D0 (en) 2010-02-15 2010-03-31 Cambridge Entpr Ltd Compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
HK1219722A1 (zh) 2013-06-21 2017-04-13 Takeda Pharmaceutical Company Limited 1-磺酰基派啶衍生物作为前动力蛋白受体的调节剂
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919624A1 (de) 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
PT533268E (pt) 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
ATE201403T1 (de) * 1993-03-16 2001-06-15 Pfizer Naphtalinderivate
EP0639568A1 (fr) * 1993-08-19 1995-02-22 Novo Nordisk A/S Dérivés de pipéridine, leur préparation et leur utilisation dans le traitement des maladies neurodégénératives
WO1995011243A1 (fr) 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
SK188399A3 (en) 2000-07-11
DE69809755T2 (de) 2003-07-17
HUP0004334A3 (en) 2002-10-28
CA2296518A1 (fr) 1999-02-04
EP1000048A1 (fr) 2000-05-17
YU2300A (sh) 2002-10-18
EE200000041A (et) 2000-10-16
US6534652B2 (en) 2003-03-18
ZA986588B (en) 1999-01-25
BR9811042A (pt) 2000-08-15
NO315609B1 (no) 2003-09-29
IS5358A (is) 2000-01-24
NO20000356D0 (no) 2000-01-24
UA69389C2 (uk) 2004-09-15
SK283918B6 (sk) 2004-05-04
AU8370398A (en) 1999-02-16
PT1000048E (pt) 2003-03-31
MA26521A1 (fr) 2004-12-20
HRP980404A2 (en) 1999-04-30
JP3895923B2 (ja) 2007-03-22
ID24583A (id) 2000-07-27
EP1000048B1 (fr) 2002-11-27
AR046193A2 (es) 2005-11-30
EE04238B1 (et) 2004-02-16
DZ2569A1 (fr) 2003-02-15
US6313118B1 (en) 2001-11-06
ES2187983T3 (es) 2003-06-16
US20010051623A1 (en) 2001-12-13
US20010051626A1 (en) 2001-12-13
NO20000356L (no) 2000-03-27
KR20010022171A (ko) 2001-03-15
TW438781B (en) 2001-06-07
JP2001510837A (ja) 2001-08-07
PL338563A1 (en) 2000-11-06
RU2194696C2 (ru) 2002-12-20
SE9702799D0 (sv) 1997-07-25
WO1999005134A1 (fr) 1999-02-04
SI1000048T1 (en) 2003-04-30
TR200000229T2 (tr) 2000-06-21
HK1025963A1 (en) 2000-12-01
IL134108A0 (en) 2001-04-30
HUP0004334A2 (en) 2001-03-28
AR013370A1 (es) 2000-12-27
DE69809755D1 (de) 2003-01-09
ATE228510T1 (de) 2002-12-15
TNSN98141A1 (fr) 2005-03-15
NZ502384A (en) 2001-05-25
CN1270585A (zh) 2000-10-18
US6410532B2 (en) 2002-06-25
AU739569B2 (en) 2001-10-18
HRP980404B1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
ATE340176T1 (de) Substituierte 6,5-heterobicyclische-derivate
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
DE69933287D1 (de) 12,13-modifizierte epothilon-derivate
NO2006016I1 (no) 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
PT993456E (pt) 4,5-diaril-imidazoles 2-substituidos
NL300150I2 (nl) 4 "-Gesubstitueerde 9-deoxo-9A-AZA-9A-homoërythromycine-A-derivaten.
DE69718771D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalinderivate
FI952424L (fi) 11,21-bisfenyyli-19-norpregaanijohdannaisia
ATE255098T1 (de) Substituierte chromanderivate
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
TR199800988A3 (tr) 5' Deoksi-Sitidin türevleri.
ATE257484T1 (de) 6,9-verbrückte erythromycin-derivate
ATE239750T1 (de) 6,11-verbrückte erythromycinderivate
ATE246199T1 (de) 3-descladinose-2,3-anhydroerythromycin-derivate
ATE227282T1 (de) 2,4-diaminopyrimidin-derivate
ATE255099T1 (de) Substituierte chromanderivate
NO20003825L (no) 1,3,4 - oxadiazolonderivater
DK1068200T3 (da) 2,4,4-trisubstituerede-1,3-dioxolanfungicider
ID24047A (id) Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on
DE69722064D1 (de) 1,25-Dihydroxy-16,22,23-trisdehydro-Cholecalciferol-Derivate